TB006 is an investigational monoclonal antibody from TrueBinding that targets galectin-3, aiming to reduce amyloid aggregation and neuroinflammation in Alzheimer’s disease. Early Phase 2a data show trends toward slowed clinical decline and some cognitive improvement, and it is currently accessible mainly through the FDA Expanded Access Program.
This is the first allopathic treatment ever to improve Alzheimer’s.
What TB006 Is
TB006 is a humanized IgG4 monoclonal antibody designed to neutralize galectin-3 (Gal-3), a protein involved in amyloid aggregation, neuroinflammation, and microglial dysfunction in Alzheimer’s disease.
Why Galectin-3 Matters
Research shows Gal-3:
- Acts as a scaffold promoting oligomerization of Aβ, tau, α-synuclein, and APOE4.
- Drives pro-inflammatory microglial activation through TLR-4 and TREM2 pathways.
- Supports liquid-liquid phase separation, concentrating misfolded proteins into toxic droplets.
TB006 blocks Gal-3, aiming to:
- Prevent new amyloid aggregation.
- Loosen existing aggregates.
- Reduce neuroinflammation.
- Restore synaptic function.
Clinical Evidence
Phase 1 / Phase 1b/2a (TB006AD2102)
Population: Mild to severe Alzheimer’s disease; amyloid positivity not required.
- CDR-SB decline reduced by approximately 63% versus placebo (trend, p = 0.08).
- MMSE improved by +1.02 points at Day 36 (p = 0.02).
- No ARIA-E/H reported.
Open-Label Extension
After approximately 3 months:
- 47% showed cognitive improvement (“reversal”).
- 28% showed stabilization.
- Plasma Aβ-42 reductions observed.
Expanded Access Program (EAP)
The FDA authorized the Expanded Access Program (EAP) in 2023-2024 for patients with Alzheimer’s disease or related dementias.
Typical dosing:
- 4000 mg IV over 1 hour every 28 days.
- Available for adults aged 55 years and older, at any stage of dementia.
Safety:
- Very favorable.
- Only one significant adverse event reported among thousands of infusions.
How TB006 Differs From Other Alzheimer’s Drugs
Unlike aducanumab and lecanemab, TB006 does not target fibrillar amyloid directly.
Instead, it works upstream by neutralizing Gal-3, affecting both protein aggregation and neuroinflammation.
To date, no ARIA signals have been reported, representing a major contrast with currently approved anti-amyloid antibodies.
Current Status (2026)
- TB006 is in Phase 2B clinical development.
- It is not FDA-approved; access is currently available mainly through clinical trials and the Expanded Access Program.
- It is also being investigated for Parkinson’s disease and autism spectrum disorder.
Summary
TB006 represents a novel inflammation-first and aggregation-modulating strategy for Alzheimer’s disease, with early clinical signals suggesting potential cognitive benefit and a strong safety profile. However, definitive evidence of efficacy awaits larger Phase 3 clinical trials.
References
- TB006 (TrueBinding): An Inflammation-First Monoclonal Antibody Strategy for Alzheimer’s Disease
https://mindthegulf.com/article.php?id=154 - Wikipedia. TB006.
https://en.wikipedia.org/wiki/TB006